With the emergence of new drugs such as SGLT2 inhibitors and the GLP-1 receptor agonist, for T2D patients with the risk of cardiovascular events, the EMPA-REG OUTCOME [6] and CANVAS [7] has been mentioned that SGTLT2 inhibitors and the GLP-1 receptor agonist have protection effects on the incidence and mortality of cardiovascular events. Here, GLP1R is linked to type 2 diabetes mellitus.